Chemotherapy

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

By

Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.

Serum IL-12 May Predict for Chemotherapy-Related Fatigue in Early-Stage Breast Cancer

Serum IL-12 May Predict for Chemotherapy-Related Fatigue in Early-Stage Breast Cancer

By

In this study, researchers sought to identify physical, neurocognitive, and serologic markers that may correlate with self-reported fatigue before and after (neo)adjuvant chemotherapy for patients with early-stage breast cancer.

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

By

Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.

What You Do Not Know Could Hurt You: What Women Wish Their Doctors Had Told Them About Chemotherapy Side Effects on Memory and Response to Alcohol

What You Do Not Know Could Hurt You: What Women Wish Their Doctors Had Told Them About Chemotherapy Side Effects on Memory and Response to Alcohol

[Breast Cancer: Basic and Clinical Research] This research examines the incidence of alcohol and memory-related side effects of chemotherapy in female cancer patients.

Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy

Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy

By

Researchers sought to evaluate the incidence of cancer-related cognitive impairment in patients with breast cancer in a large prospective, longitudinal, nationwide study. These findings address limitations in previous research.

Drug-Drug Interaction Between Capecitabine and PPIs Reduces Survival in GI Cancers

Drug-Drug Interaction Between Capecitabine and PPIs Reduces Survival in GI Cancers

By

Drug-drug interaction between capecitabine and common heartburn medications has a negative effect on progression-free survival and overall survival in patients with GI cancer.

Subtype of Glioblastoma Multiforme Responds to Antiangiogenic Chemotherapy

By

Although previous clinical trials have demonstrated that antiangiogenetic chemotherapy is not effective in GBM, researchers conducted a retrospective of review of perfusion MR images to determine if a phenotypic subtype of GBM may respond to antiangiogenic chemotherapy.

Biomarker Predicts Anthracycline-caused Heart Damage in Women with Breast Cancer

Biomarker Predicts Anthracycline-caused Heart Damage in Women with Breast Cancer

By

Investigators have identified a genetic biomarker that can help determine congestive heart failure risk in individuals undergoing chemotherapy for breast cancer.

Can Depression Reduce Chemotherapy Tolerability, Effectiveness in Advanced Lung Cancer?

Can Depression Reduce Chemotherapy Tolerability, Effectiveness in Advanced Lung Cancer?

By

New evidence indicates that depression can impact cancer outcomes following chemotherapy.

Chemo-related Cardiotoxicity May Be Worse in Diabetes Patients

Chemo-related Cardiotoxicity May Be Worse in Diabetes Patients

Patients with diabetes showed more early warning signs of heart failure following chemotherapy.

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

By

A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.

Panitumumab Plus Accelerated RT Not Effective for Locoregionally Advanced HNSCC

Panitumumab Plus Accelerated RT Not Effective for Locoregionally Advanced HNSCC

By

Progression-free survival with panitumumab plus accelerated-fractionation radiotherapy was compared with that of cisplatin plus standard-fractionation radiotherapy in patients with locoregionally advanced HNSCC in a recently published study.

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

By

A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

[Clinical Medicine Insights: Oncology] This research examines the various mechanisms of resistance to chemotherapy in metastatic CRPC and the potential role of emerging regimens and agents in varying clinical phases of development.

Primary Cytoreductive Surgery Associated With Improved Survival in Ovarian Cancer

Primary Cytoreductive Surgery Associated With Improved Survival in Ovarian Cancer

By

The benefits of primary cytoreductive surgery relative to neoadjuvant chemotherapy remain uncertain; therefore, researchers performed a retrospective data analysis to compare overall survival of surgery with that of neoadjuvant chemotherapy in advanced-stage epithelial ovarian cancer.

'Just Bag It' Campaign Aims to Promote Safe Vincristine Handling

'Just Bag It' Campaign Aims to Promote Safe Vincristine Handling

By

The NCCN campaign was developed to ensure the proper administration of vincristine and to render it impossible to accidentally administer the medication into the spinal fluid.

How We Developed a New Protocol for Treatment of Urethral Carcinoma

How We Developed a New Protocol for Treatment of Urethral Carcinoma

Faced with a harsh treatment option, a patient with genitourinary cancer helps create a treatment plan that preserves his self-image.

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

By

Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

By

The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous NSCLC.

GERD Medications May Affect Absorption of Oral Chemotherapeutic Agents

GERD Medications May Affect Absorption of Oral Chemotherapeutic Agents

By

What is the interaction between oral chemotherapy and GERD medicines?

Low-dose Dexamethasone Premedication May Be Preferred for Weekly Docetaxel Regimens

Low-dose Dexamethasone Premedication May Be Preferred for Weekly Docetaxel Regimens

By

Low-dose dexamethasone may be preferred as a premedication protocol for patients receiving weekly docetaxel regimens due a significantly lower risk of infection compared with a higher dose regimen.

Pregnancy Screening Inconsistent in Female Adolescents Before Chemotherapy Exposure

Pregnancy Screening Inconsistent in Female Adolescents Before Chemotherapy Exposure

By

Pregnancy screening rates before teratogenic exposures are low for female adolescent patients with acute leukemia and those with ER visits including abdominal/pelvic CT.

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

NeoadjuvantcChemotherapy (NACT) use went up from 2003 to 2012; linked to shorter overall survival in stage IIIC but not stage IV disease.

Drug Prevents Heart Damage in Pediatric Patients Receiving Chemotherapy

Drug Prevents Heart Damage in Pediatric Patients Receiving Chemotherapy

By

Dexrazoxane has cardioprotective properties that can prevent long-term cardiotoxicity in pediatric patients receiving chemotherapy, according to a review of the medical literature on cardiotoxic effects of anthracycline treatment.

Chemotherapy-Induced Dormancy Improves Immunotherapy for Breast Cancer

Chemotherapy-Induced Dormancy Improves Immunotherapy for Breast Cancer

By

Inducing quiescent dormancy with conventional chemotherapy makes cancer cells more susceptible to immunotherapy, thereby minimizing potential for tumor recurrence.

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

By

The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.

Recently Discovered microRNA Controls Response to Oxaliplatin in Colorectal Cancer

By

Danish researchers identified a microRNA shown to predict whether a patient with colorectal cancer would be resistant to oxaliplatin treatment, a discovery that holds promise of improving both current treatment options and development of future treatment strategies.

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

By

The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).

Managing Toxicity Risks of Dose-Dense Chemotherapy in the Obese

Managing Toxicity Risks of Dose-Dense Chemotherapy in the Obese

By

Risks for severe toxicities in obese patients receiving dose-dense chemotherapy are associated with measures used to determine dose, according to a retrospective evaluation of select participants in the GAIN study.

Hyper-CVAD + Ponatinib May Be Superior to Hyper-CVAD + Dasatinib in Ph+ ALL

By

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs